| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYnote-028 study
|
?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU; Le Tourneau C.; Hollebecque A. |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Raftopoulos H; Patnaik A.; Saraf S; Fiore J; Su W.-C; Papadimitrakopoulou V.A; Wu C.-L; Sequist L.V; Gadgeel S.M; CHIH-HSIN YANG; Chih-Hsin Yang;Gadgeel S.M;Sequist L.V;Wu C.-L;Papadimitrakopoulou V.A;Su W.-C;Fiore J;Saraf S;Raftopoulos H;Patnaik A. |
| 國立成功大學 |
2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Yang, J.C.-H.;Gadgeel, S.M.;Sequist, L.V.;Wu, C.-L.;Papadimitrakopoulou, V.A.;Su, W.-C.;Fiore, J.;Saraf, Saraf S.;Raftopoulos, H.;Patnaik, A. |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 國立臺灣大學 |
2016 |
Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study
|
Zhu, A.; Knox, J.; Kudo, M.; Chan, S.; Finn, R.; Siegel, A.; Ma, J.; Watson, P. A.; Cheng, A-L.; 鄭安理 |
| 臺大學術典藏 |
2020-10-22T07:41:44Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
WEI-LI CHEN; Liu J.-H.; Yao M.; Hsiao C.-C.; Hsiao C.-C.;Yao M.;Liu J.-H.;Wei-Li Chen |
| 臺大學術典藏 |
2021-07-22T03:35:56Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Hsiao C.-C.; Yao M.; LIU JIA-HAU; Chen W.-L. |
| 臺大學術典藏 |
2021-01-05T03:34:30Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Chen W.-L.; Liu J.-H.; MING YAO; Hsiao C.-C. |
| 臺大學術典藏 |
2022-04-25T07:36:14Z |
Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation
|
Hsiao C.-C.; Yao M.; JIA-HAU LIU; Chen W.-L. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 Study
|
Rudin C.M.;Awad M.M.;Navarro A.;Gottfried M.;Peters S.;Csoszi T.;Cheema P.K.;Rodriguez-Abreu D.;Wollner M.;Chih-Hsin Yang;Mazieres J.;Orlandi F.J.;Luft A.;G?M?? M.;Kato T.;Kalemkerian G.P.;Luo Y.;Ebiana V.;Pietanza M.C.;Kim H.R.;Keynote-604 Investigators; Rudin C.M.; Awad M.M.; Navarro A.; Gottfried M.; Peters S.; Csoszi T.; Cheema P.K.; Rodriguez-Abreu D.; Wollner M.; CHIH-HSIN YANG; Mazieres J.; Orlandi F.J.; Luft A.; G?m?? M.; Kato T.; Kalemkerian G.P.; Luo Y.; Ebiana V.; Pietanza M.C.; Kim H.R.; KEYNOTE-604 Investigators |
| 臺大學術典藏 |
2021-04-26T08:05:25Z |
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|
Cortes J.; Cescon D.W.; Rugo H.S.; Nowecki Z.; Im S.-A.; Yusof M.M.; Gallardo C.; Lipatov O.; Barrios C.H.; Holgado E.; Iwata H.; Masuda N.; Otero M.T.; Gokmen E.; Loi S.; Guo Z.; Zhao J.; Aktan G.; Karantza V.; Schmid P.; Luis F.; Gonzalo G.A.; Diego K.; Ruben K.; Matias M.; Mirta V.; Sally B.-H.; Stephen B.; Philip C.; Sherene L.; Dhanusha S.; Andrea G.; Donatienne T.; Carlos B.; Leandro B.; Fabiano C.; Ruffo D.F.J.; Roberto H.; Domicio Carvalho L.; Fernando Cezar Toniazzi L.; Roberto Odebrecht R.; Antonio Orlando S.N.; Felipe S.; David C.; Danielle C.; Cristiano F.; Xinni S.; Joanne Y.; Alejandro A.; Carlos G.; Claudio S.; Cesar S.; Eduardo Y.; Alvaro G.D.; Jesus S.; Petra H.; Zdenek K.; Bohuslav M.; Katarina P.; Jana P.; Vesna G.; Erik J.; Jeanette J.; Soren L.; Tamas L.; Herve B.; Isabelle D.; Anthony G.; Anne-Claire H.-B.; Luis T.; Jens-Uwe B.; Peter F.; Dirk F.; Nadia H.; Jens H.; Anna K.F.D.S.; Christian K.; Sibylle L.; Diana L.; Tjoung-Won P.-S.; Raquel Von S.; Pauline W.; Louis C.; Ava K.; Kai Cheong Roger N.; Peter A.; Tibor C.; Zsuzsanna K.; Laszlo L.; Karoly M.; Gabor R.; John C.; Catherine K.; Seamus O.R.; Saverio C.; Antonietta D.A.; Enrico R.; Tomoyuki A.; Takaaki F.; Kenichi I.; Takashi I.; Yoshinori I.; Tsutomu I.; Hiroji I.; Yoshimasa K.; Koji M.; Yasuo M.; Hirofumi M.; Seigo N.; Naoki N.; Shoichiro O.; Akihiko O.; Yasuaki S.; Eiji S.; Masato T.; Yuko T.; Kenji T.; Koichiro T.; Junichiro W.; Naohito Y.; Yutaka Y.; Teruo Y.; Anita B.; Mastura M.Y.; Angel G.V.; Alejandro J.R.; Jorge M.R.; Flavia M.-V.; Jessica R.C.; Karin B.; Vivianne T.-H.; David P.; Ewa C.; Ewa N.-Z.; Zbigniew N.; Barbara R.; Joanna S.; Cezary S.; Rafal T.; Bogdan Z.; Alexander A.; Natalia F.; Oleg L.; Andrey M.; Vladimir M.; Guzel M.; Jin Hee A.; Seock-Ah I.; Keun Seok L.; Kwong Hwa P.; Yeon Hee P.; Begona B.D.L.H.; Javier C.; Josefina C.J.; Luis D.L.C.M.; Jose G.S.; Maria G.; Esther H.; Esther Z.A.; Chien-Ting L.; Mei-Ching L.; Chiun-Sheng H.; Chao-Jung T.; Ling-Ming T.; Cagatay A.; Gul B.; Irfan C.; Erhan G.; Seyda G.; Nil M.M.; Mustafa O.; Ozgur O.; Sinan Y.; Steve C.; Janine G.; Iain M.; Peter S.; Nicholas T.; Mark T.; Christopher T.; Duncan W.; Hryhoriy A.; Oleksandr B.; Igor B.; Oleksii K.; Olena K.; Hanna K.; Anna K.; Iurii L.; Alla N.; Natalya O.; Olga P.; Andrii R.; Sergii S.; Yaroslav S.; Dmytro T.; Grygorii U.; Ihor V.; Sibel B.; Madhu C.; Michael C.; Patrick C.; Scott C.; Jennifer D.; Keerthi G.; Jeffrey H.; Kent H.; William I.; Randa L.; Janice L.; Raul M.; Susan M.; Rita N.; Ira O.; Coral O.; Timothy P.; Amit P.; Brian P.; Hope R.; Irina R.; Michael S.; Robert S.; Michael S.; Laura S.; Bradley S.; Michaela T.; Frances V.-A.; KEYNOTE-355 Investigators; CHIUN-SHENG HUANG |
| 臺大學術典藏 |
2021-01-28T01:06:20Z |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial
|
Shitara K.;?Zg?Ro?Lu M.;Bang Y.-J.;Di Bartolomeo M.;Mandal? M.;Ryu M.-H.;Fornaro L.;Olesi?Ski T.;Caglevic C.;Chung H.C.;Muro K.;Goekkurt E.;Mansoor W.;Mcdermott R.S.;Shacham-Shmueli E.;Chen X.;Mayo C.;Kang S.P.;Ohtsu A.;Fuchs C.S.;Lerzo G.;O'Connor J.M.;Mendez G.A.;Lynam J.;Tebbutt N.;Wong M.;Strickland A.;Karapetis C.;Goldstein D.;Vasey P.;Van Laethem J.-L.;Van Cutsem E.;Berry S.;Vincent M.;Muller B.;Rey F.;Zambrano A.;Guerra J.;Krogh M.;Baeksgaard L.;Yilmaz M.;Elme A.;Magi A.;Auvinen P.;Alanko T.;Moehler M.;Kunzmann V.;Seufferlein T.;Thuss-Patience P.;Goekkurt E.;Hoehler T.;Haag G.;Al-Batran S.-E.;Castro H.;Lopez K.;Aguilar Vasquez M.;Sandoval M.;Lam K.O.;Cuffe S.;Kelly C.;Geva R.;Shacham-Shmueli E.;Hubert A.;Beny A.;Brenner B.;Giuseppe A.;Falcone A.;Maiello E.;Passalacqua R.;Montesarchio V.;Hara H.;Chin K.;Nishina T.;Komatsu Y.;Machida N.;Hironaka S.;Satoh T.;Tamura T.;Sugimoto N.;Cho H.;Omuro Y.;Kato K.;Goto M.;Hyodo I.;Yoshida K.;Baba H.;Esaki T.;Furuse J.;Wan Mohammed W.Z.;Hernandez Hernandez C.;Casas Garcia J.;Dominguez Andrade A.;Clarke K.;Hjortland G.;Glenjen N.;Kubiatowski T.;Jacek J.;Wojtukiewicz M.;Lazarev S.;Lancukhay Y.;Afanasayev S.;Moiseyenko V.;Kostorov V.;Protsenko S.;Shirinkin V.;Sakaeva D.;Fadeeva N.;Yong W.P.;Ng C.H.M.;Robertson B.;Rapaport B.;Cohen G.;Dreosti L.;Ruff P.;Jacobs C.;Landers G.;Szpak W.;Roh S.-Y.;Lee J.;Kim Y.H.;Bang Y.-J.;Chung H.C.;Ryu M.-H.;Alsina Maqueda M.;Longo Munoz F.;Cervantes Aguilar A.;Aranda Aguilar E.;Garcia Alfonso P.;Rivera F.;Feliu Batle J.;Pazo Cid R.;Kun-Huei Yeh;Chen J.-S.;Chao Y.;Yen C.-J.;?Zg?Ro?Lu M.;Kara O.;Yalcin S.;Hochhauser D.;Chau I.;Benson A.;Shankaran V.;Shaib W.;Philip P.;Sharma V.;Siegel R.;Sun W.;Wainberg Z.;George B.;Bullock A.;Myrick S.;Faruol J.;Siegel R.;Larson T.;Becerra C.;Ratnam S.;Richards D.A.;Riche S.L.;Keynote-061 Investigators; Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators |
| 臺大學術典藏 |
2020-10-06T03:31:14Z |
Pembrolizumab-induced linear psoriasis
|
Huang P.-W.;Chia-Yu Chu; Huang P.-W.; CHIA-YU CHU |
| 臺大學術典藏 |
2021-11-10T05:59:11Z |
Pembrolizumab-induced linear psoriasis
|
PO-WEI HUANG; Chu C.-Y. |
| 國立臺灣大學 |
2015 |
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
|
Yang, James Chin-Hsin; Ahn, Myung-Ju; Nakagawa, Kazuhiko; Tamura, Tomohide; Barraclough, Helen; Enatsu, Sotaro; Cheng, Rebecca; Orlando, Mauro; 楊志新 |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT
|
Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. |
| 國立交通大學 |
2014-12-08T15:33:31Z |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen, Ruey-Shyang; Ko, Jen-Chung; Chiu, Hsien-Chun; Wo, Ting-Yu; Huang, Yi-Jhen; Tseng, Sheng-Chieh; Chen, Huang-Jen; Huang, Yu-Ching; Jian, Yi-Jun; Lee, Wei-Ting; Lin, Yun-Wei |
| 國立臺灣大學 |
2013 |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen, Ruey-Shyang; Ko, Jen-Chung; Chiu, Hsien-Chun; Wo, Ting-Yu; Huang, Yi-Jhen; Tseng, Sheng-Chieh; Chen, Huang-Jen; Huang, Yu-Ching; Jian, Yi-Jun; Lee, Wei-Ting; Lin, Yun-Wei |
| 臺大學術典藏 |
2021-03-11T07:58:34Z |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen R.-S.; JEN-CHANG KO; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W. |
| 臺大學術典藏 |
2021-03-11T08:29:39Z |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen R.-S.; JEN-CHANG KO; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W. |
| 臺大學術典藏 |
2021-03-11T08:34:25Z |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen R.-S.; JEN-CHANG KO; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W. |
| 臺大學術典藏 |
2021-10-04T07:15:48Z |
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
|
Chen R.-S.; JEN-CHANG KO; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W. |
| 臺大學術典藏 |
2021-04-29T02:38:42Z |
Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer
|
Anonymous |
| 臺大學術典藏 |
2021-07-13T06:04:41Z |
Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer
|
LEE JIH-HSIANG; Yu C.-J.; Chen K.-Y.; Shih J.-Y.; Lin Y.-L.; Yang C.-H. |
